Glyphic Biotechnologies Is A Biotechnology Startup Founded In 2021 And Based In Berkeley, California, With An Additional Office In New York City. The Company Focuses On Advancing Proteomics Through Its Innovative Protein Sequencing Platform, Which Utilizes A Single-molecule, Massively Parallel Technology. This Allows For The Simultaneous Sequencing Of Billions Of Proteins, Providing Researchers With Deeper Insights Into Biology And Disease. The Company Offers Advanced Protein Sequencing Technology And Services Tailored For Researchers And Institutions In Biological, Medical, And Pharmaceutical Fields. Glyphic Biotechnologies Also Explores Licensing Its Proprietary Technology To Other Biotech And Pharmaceutical Companies. Its Platform Aims To Enhance Proteomics Research, Facilitating Breakthroughs In Understanding Disease Mechanisms And Accelerating Drug Discovery. With A Team Of Around 29 Employees, Glyphic Has Secured Early Venture Capital Funding To Support Its Development And Commercialization Efforts.